T-TAS® WS Method Comparison

Ostensibly Healthy Donors

Inclusion Criteria:

• Males and females age 21 years or older.

• Able and willing to provide written informed consent.

Exclusion Criteria:

• Hospitalization or doctor's visits within prior 30 days, except for routinecheckup/physical examination.

• Use of antiplatelet therapy within the past 7 days, e.g. aspirin, clopidogrel,prasugrel, ticagrelor, cilostazol.

• Use of anticoagulant drugs within the past 7 days, e.g. heparin, bivalirudin,warfarin, rivaroxaban, and apixaban.

• Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 suchas naproxen or ibuprofen within the past 3 days, unless confirmed to not inhibitplatelet activity (such as celecoxib).

• History of anemia.

• Known thrombocytopenia (platelet count < 100,000/μL).

• Significant renal dysfunction or dialysis.

• History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann'sthrombasthenia or Bernard-Soulier syndrome.

• History of hemophilia or bleeding disorders.

• Known active gastrointestinal disease including peptic ulcers, gastro-esophagealreflux disease (GERD), and hyperacidity.

• Currently participating in a study involving an investigational drug or compoundknown to affect coagulation or hemostasis.

• Subjects with significant past medical history as determined by the Investigatorthat would pose safety concerns or interfere with the study goals.

Antiplatelet Therapy Subjects

Inclusion Criteria:

• Males and females age 21 years or older.

• One of the following antiplatelet therapy regimens:

• Aspirin monotherapy:

• 81 mg or higher aspirin daily for 1 or more days

• Dual antiplatelet therapy:

• 81 mg or higher aspirin plus either 1) ≥300 mg clopidogrel loading dose within theprior 5 days followed by 75 mg daily clopidogrel, or 2) 75 mg daily clopidogreldaily for ≥5 days.

• 81 mg or higher aspirin plus either 1) 60 mg prasugrel loading dose within the prior 5 days followed by either 5 or 10 mg daily prasugrel, or 2) 5 or 10 mg dailyprasugrel daily for ≥5 days.

• 81 mg aspirin plus either 1) 180 mg ticagrelor loading dose within the prior 5 daysfollowed by 2x90 mg daily ticagrelor, or 2) 2x90 mg daily ticagrelor daily for ≥5days.

• Able and willing to provide written informed consent.

Exclusion Criteria:

• Use of antiplatelet therapy other than aspirin, clopidogrel, prasugrel, orticagrelor (e.g. cilostazol, abciximab, eptifibatide) within the past 7 days.

• Use of anticoagulant drugs within the past 7 days, e.g. heparin, bivalirudin,warfarin, rivaroxaban, and apixaban.

• Significant renal dysfunction or dialysis.

• Known thrombocytopenia (platelet count < 100,000/μL).

• History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmannthrombasthenia or Bernard-Soulier syndrome.

• History of hemophilia or bleeding disorders.

• Females who are in the last trimester of pregnancy or are breastfeeding.

• Known active gastrointestinal disease including peptic ulcers, gastro-esophagealreflux disease (GERD), and hyperacidity.

• Currently participating in a study involving an investigational drug or compoundknown to affect coagulation or hemostasis.

• Subjects with significant past medical history as determined by the Investigatorthat would pose safety concerns or interfere with the study goals.

Von Willebrand Disease Subjects

Inclusion Criteria:

• Males and females age 21 years or older.

• Prior diagnosis of von Willebrand disease type 1, 2A, 2B, 2M, or 3

• Able and willing to provide written informed consent.

Exclusion Criteria:

• Prior diagnosis of von Willebrand disease type 2N

• Use of antiplatelet therapy besides aspirin within the past 14 days.

• Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin,warfarin, rivaroxaban, and apixaban.

• Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 suchas naproxen or ibuprofen within the past 7 days, unless confirmed to not inhibitplatelet activity (such as celecoxib).

• Significant renal dysfunction or dialysis.

• Known thrombocytopenia (platelet count < 100,000/μL).

• Currently participating in a study involving an investigational drug or compoundknown to affect coagulation or hemostasis.

• Subjects with significant past medical history as determined by the Investigatorthat would pose safety concerns or interfere with the study goals.